Literature DB >> 9235954

p38-2, a novel mitogen-activated protein kinase with distinct properties.

B Stein1, M X Yang, D B Young, R Janknecht, T Hunter, B W Murray, M S Barbosa.   

Abstract

Mitogen-activated protein (MAP) kinases are involved in many cellular processes. Here we describe the cloning and characterization of a new MAP kinase, p38-2. p38-2 belongs to the p38 subfamily of MAP kinases and shares with it the TGY phosphorylation motif. The complete p38-2 cDNA was isolated by polymerase chain reaction. It encodes a 364-amino acid protein with 73% identity to p38. Two shorter isoforms missing the phosphorylation motif were identified. Analysis of various tissues demonstrated that p38-2 is differently expressed from p38. Highest expression levels were found in heart and skeletal muscle. Like p38, p38-2 is activated by stress-inducing signals and proinflammatory cytokines. The preferred upstream kinase is MEK6. Although p38-2 and p38 phosphorylate the same substrates, the site specificity of phosphorylation can differ as shown by two-dimensional phosphopeptide analysis of Sap-1a. Additionally, kinetic studies showed that p38-2 appears to be about 180 times more active than p38 on certain substrates such as ATF2. Both kinases are inhibited by a class of pyridinyl imidazoles. p38-2 phosphorylation of ATF2 and Sap-1a but not Elk1 results in increased transcriptional activity of these factors. A sequential kinetic mechanism of p38-2 is suggested by steady state kinetic analysis. In conclusion, p38-2 may be an important component of the stress response required for the homeostasis of a cell.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9235954     DOI: 10.1074/jbc.272.31.19509

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation.

Authors:  G Pearson; J M English; M A White; M H Cobb
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

2.  beta(3)-adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility.

Authors:  P Varghese; R W Harrison; R A Lofthouse; D Georgakopoulos; D E Berkowitz; J M Hare
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

3.  The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS.

Authors:  Adam D Bachstetter; Linda J Van Eldik
Journal:  Aging Dis       Date:  2010-09-24       Impact factor: 6.745

4.  Redox/ROS regulation of lipopolysaccharide-induced mitogen-activated protein kinase (MAPK) activation and MAPK-mediated TNF-alpha biosynthesis.

Authors:  J J Haddad; S C Land
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

5.  Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1.

Authors:  S H Yang; A J Whitmarsh; R J Davis; A D Sharrocks
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

6.  Role of p38 MAP kinase in LPS-induced airway inflammation in the rat.

Authors:  E B Haddad; M Birrell; K McCluskie; A Ling; S E Webber; M L Foster; M G Belvisi
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

7.  Activation of mitogen activated protein kinases in post-infarcted patients.

Authors:  Reza Akbarzadeh Najar; Sayyed Mohammad Hossein Ghaderian; Akram Sadat Tabatabaei Panah
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

8.  P38 mitogen activated protein kinase expression and regulation by interleukin-4 in human B cell non-Hodgkin lymphomas.

Authors:  Hu Ding; Ali M Gabali; Stephen D Jenson; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Hematop       Date:  2009-10-21       Impact factor: 0.196

9.  ROS Control Mitochondrial Motility through p38 and the Motor Adaptor Miro/Trak.

Authors:  Valentina Debattisti; Akos A Gerencser; Masao Saotome; Sudipto Das; György Hajnóczky
Journal:  Cell Rep       Date:  2017-11-07       Impact factor: 9.423

Review 10.  The p38alpha mitogen-activated protein kinase as a central nervous system drug discovery target.

Authors:  Aaron S Borders; Lucia de Almeida; Linda J Van Eldik; D Martin Watterson
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.